October 25, 2024
Hi Erica, Please find our social listening snapshot below for 10/12 - 10/25, along with a dashboard snapshot PDF attached.
LEO Pharma
Top LEO Pharma Company & Drug Discussions
- Company Mentions:
- LEO Pharma presents ADBRY and delgocitinib data at the 2024 Fall Clinical Dermatology Conference. Media coverage is focused on ADBRY’s long-term efficacy in AD, based on results from the Phase III ECZTEND study. (Press Release on BioSpace, Dermatology Today, Pharmaceutical Technology, Medical Professionals Reference, HCP Live)
- LEO Pharma launches its “Talk to the Hand” campaign to spread awareness about CHE. (Fierce Pharma, Press release)
- In a recent Q&A, LEO Pharma CEO Christophe Bourdon discusses the company’s presentations at EADV 2024, highlighting delgocitinib’s recent European approval and anticipated U.S. FDA review. (Dermatology Times)
- LEO Pharma hires a head of international relations, ahead of a possible IPO. (MedWatch)
- tralokinumab (ADBRY):
- Results from the TRACE study suggest that tralokinumab is a promising long-term treatment for head and neck ADs, showing efficacy after up to 9 months of use. (Healio, MIMS Pharmacy)
- On Reddit, users discuss switching from DUPIXENT to ADBRY or RINVOQ with mostly positive results:
- “I’ve switched from Dupixent to Adbry couple months ago [..] doing great so far!”
- ”[..] I was worried adbry wouldn’t be as effective but it’s been great so far, no side effects!”
- “I was on Dupixent for a year [..] I moved to Rinvoq, but had to give up on that as well. The past year I have been on Adtralza/Adbry, but similar to Dupixent, its efficacy started to wane. I got moved to weekly dosing which helped.”
- “Super sad dupixent stopped working but rinvoq has kept me clear.”
- “I was on dupixent years ago stopped and have just started Tralokinumab too. [..] I prefer this as it being a pen much easier to inject […] I’ve not really seen any differences yet”
- In another thread on Reddit, a user inquires about side effects associated with ADBRY and a COVID-19 booster shot.
- delgocitinib:
- Germany becomes the first country in the world to launch Anzupgo (delgocitinib). (Press release, Dermatology Times)
- An HCP addresses common barriers in recognizing and treating CHE and its significant impact on quality of life—mentioning the US market’s pending approval of delgocitinib. (Dermatology Times)
Other top Atopic Dermatitis (AD) & Chronic Hand Eczema (CHE) Discussions
- Eli Lilly presents new data from the Phase 3b ADapt study of EBGLYSS at the 2024 Fall Clinical Dermatology Conference. (Benzinga)
- An analysis of Abbvie’s Phase III trials for RINVOQ finds that the drug shows long-term benefits in teens with AD. (MedPage Today)
- A Reddit user voices skepticism about the hype surrounding DUPIXENT as an eczema treatment; however, many responded with overwhelmingly positive experiences, citing life-changing improvements and minimal side effects.
- A meta-analysis published in the Cochrane Library identifies the safest, most effective topical treatments for AD: high-potency corticosteroids, JAK inhibitors, and tacrolimus 0.1%. (MedPage Today)
- In honor of National Eczema Awareness Month, Healio hosts a Q&A with an HCP to explore the latest research and treatment advancements for eczema—mentioning rocatinlimab, DUPIXENT, ADBRY, lutikizumab, and EBGLYSS. (Healio)
- Recent research presented at AMCP Nexus 2024 highlighted the burden of flares on patients with AD and the importance of addressing unmet needs. (Drug Topics)
- A study presented at the 2024 ACAAI Annual Scientific Meeting finds that elimination diets in the case of AD only mildly improves AD lesions in 35% of children. (News-Medical, Medical Xpress, Dermatology Times)
- Research published in the International Journal of Dermatology suggests a link between Prurigo Nodularis and AD. (Medical Dialogues)
- A study published by the Yale School of Medicine suggests a link between eczema and poorer leg artery function. (MedicineNet)
- The FDA’s approval of EBGLYSS continues to be covered by media, with an article focusing on the drug’s pricing. (MMIT Network)
Dr. Reddy’s Laboratories
- Company Mentions:
- Dr. Reddy’s wins the the Supply Chain Productivity Excellence Award at the Pharma Manufacturing & Automation Excellence Awards 2024. (X)
- Dr. Reddy’s is named by Science Magazine in Top 20 Global Pharma Employers List for the 3rd consecutive year. (Press release)
- denosumab:
- Teva’s denosumab biosimilar candidate is accepted for review by the FDA and EMA. (AJMC, X)
- A new study finds that bone resorption inhibitors like denosumab should be prescribed to women with early breast cancer (EBC) receiving aromatase inhibitors to protect their bone health. (The Breast)
- COYA 302:
- The Chairman and CEO of Coya Therapeutics publishes an article, “Fighting Neurodegenerative Diseases: The Need for Combination Biologics”. (BioProcess International)
- Coya Therapeutics secures $10M in private placement. (Investing)
Paratek Pharmaceuticals
- omadacycline (NUZYRA):
- Data from several studies of NUZYRA is presented at IDWeek 2024. (X, Press release)
- An article covering case studies on NTM presented at IDWeek 2024 highlights NUZYRA. (Clinical Trials Arena)
- A post-marketing study of NUZYRA finds positive top-line results of NUZYRA in the treatment of patients with CABP. (Press release)